Cargando…

DAA treatment failures in a low-resource setting with a high burden of hepatitis C infections: a case series

Globally, 58 million people are living with hepatitis C virus (HCV) infection and 1.5 million new patients are infected every year. The advent of direct acting antivirals (DAAs) has revolutionized the treatment of HCV, opening the door to the ambitious World Health Organization HCV infection elimina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zahid, Hassaan, Aslam, Khawar, Dahl, Elin Hoffmann, Abbassi, Waqas, Adan, Suleiman, Van den Bergh, Rafael, Balinska, Marta A, Luck, Nasir Hassan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127947/ https://www.ncbi.nlm.nih.gov/pubmed/35619685 http://dx.doi.org/10.1093/omcr/omac049

Ejemplares similares

Leaving no one behind: Towards equitable global elimination of hepatitis C
por: Dahl, Elin Hoffmann, et al.
Publicado: (2020)

Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure
por: Danishwar, Mahmood, et al.
Publicado: (2022)

On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era
por: Busschots, Dana, et al.
Publicado: (2021)

Clinical outcomes of DAA and related techniques in hip arthroplasty
por: Driesman, Adam, et al.
Publicado: (2023)

Cost‐effectiveness of screening and treatment using direct‐acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan
por: Mafirakureva, Nyashadzaishe, et al.
Publicado: (2020)

The value of case reports in democratising evidence from resource-limited settings: results of an exploratory survey
por: Balinska, Marta A., et al.
Publicado: (2020)

Treatment of hepatitis C in HIV patients in the new DAA era
por: Soriano, Vicente
Publicado: (2014)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

Is DAA Treatment Associated with HBV Reactivation? Results from ERCHIVES
por: Butt, Adeel, et al.
Publicado: (2017)

Treatment of hepatitis C virus genotype 4 in the DAA era
por: Di Biagio, Antonio, et al.
Publicado: (2018)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

304. Hepatocellular Carcinoma Occurs Frequently and Early After Treatment in HCV Genotype 3 Infected Persons Treated with DAA Regimens
por: Un Nabi Tayyab, Ghias, et al.
Publicado: (2019)

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens
por: Tayyab, Ghias Un Nabi, et al.
Publicado: (2020)

Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis
por: Shakeri, Ahmad, et al.
Publicado: (2021)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
por: Fabrizi, Fabrizio, et al.
Publicado: (2021)

Changing Landscape of Liver Transplantation in the Post-DAA and Contemporary ART Era
por: Saeed, Huma, et al.
Publicado: (2022)

The effect of APN, hs-CRP and APN/hs-CRP in periodontitis with DAA
por: Cheng, Rui, et al.
Publicado: (2023)

“Waiting for DAAs”: A retrospective chart review of patients with untreated hepatitis C in Rwanda
por: Gupta, Neil, et al.
Publicado: (2017)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

Telehealth for Hepatitis C Care in the DAA Era; Ensuring Everyone Can Access a Cure
por: Schulz, Thomas Ray, et al.
Publicado: (2017)

A real-life study of the positive response to DAA-based therapies for hepatitis C in Brazil
por: Vivaldini, Simone Monzani, et al.
Publicado: (2021)

Factors leading to dyspepsia in renal transplant recipients
por: Nazeer, Aisha, et al.
Publicado: (2017)

Frequency of gallstones and mean BMI in decompensated cirrhosis
por: Rai, Ayesha Aslam, et al.
Publicado: (2018)

Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
por: Drazilova, Sylvia, et al.
Publicado: (2018)

Agreement and reproducibility of radiological signs in NEC using The Duke Abdominal Assessment Scale (DAAS)
por: Markiet, Karolina, et al.
Publicado: (2016)

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
por: Seo, Kwang Il, et al.
Publicado: (2017)

Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
por: de Gennaro, Nicolò, et al.
Publicado: (2020)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Hosui, Atsushi, et al.
Publicado: (2021)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Perceived Stress in Hepatitis C Virus Infected Patients under the DAA-Based Therapy
por: Danilescu, Claudia Monica, et al.
Publicado: (2022)

Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs
por: Ponnuvel, Suresh, et al.
Publicado: (2023)

Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study
por: Lanini, Simone, et al.
Publicado: (2018)

Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy)
por: Scaglione, Vincenzo, et al.
Publicado: (2020)

Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series
por: Ambarsari, Cahyani Gita, et al.
Publicado: (2020)

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects
por: Bono, Valeria, et al.
Publicado: (2022)

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era
por: Sacks‐Davis, Rachel, et al.
Publicado: (2018)

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance
por: Pascut, Devis, et al.
Publicado: (2020)

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
por: Gao, Xiuzhu, et al.
Publicado: (2020)

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan
por: Hong, Chun-Ming, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i6m4sv2f800ovebj2n5v8o52h5